180 related articles for article (PubMed ID: 24028205)
1. Successful gene therapy in older Rpe65-deficient dogs following subretinal injection of an adeno-associated vector expressing RPE65.
Annear MJ; Mowat FM; Bartoe JT; Querubin J; Azam SA; Basche M; Curran PG; Smith AJ; Bainbridge JW; Ali RR; Petersen-Jones SM
Hum Gene Ther; 2013 Oct; 24(10):883-93. PubMed ID: 24028205
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy in the second eye of RPE65-deficient dogs improves retinal function.
Annear MJ; Bartoe JT; Barker SE; Smith AJ; Curran PG; Bainbridge JW; Ali RR; Petersen-Jones SM
Gene Ther; 2011 Jan; 18(1):53-61. PubMed ID: 20703309
[TBL] [Abstract][Full Text] [Related]
3. Gene therapeutic prospects in early onset of severe retinal dystrophy: restoration of vision in RPE65 Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium.
Rolling F; Le Meur G; Stieger K; Smith AJ; Weber M; Deschamps JY; Nivard D; Mendes-Madeira A; Provost N; Péréon Y; Cherel Y; Ali RR; Hamel C; Moullier P; Rolling F
Bull Mem Acad R Med Belg; 2006; 161(10-12):497-508; discussion 508-9. PubMed ID: 17503728
[TBL] [Abstract][Full Text] [Related]
4. Long-term effect of gene therapy on Leber's congenital amaurosis.
Bainbridge JW; Mehat MS; Sundaram V; Robbie SJ; Barker SE; Ripamonti C; Georgiadis A; Mowat FM; Beattie SG; Gardner PJ; Feathers KL; Luong VA; Yzer S; Balaggan K; Viswanathan A; de Ravel TJ; Casteels I; Holder GE; Tyler N; Fitzke FW; Weleber RG; Nardini M; Moore AT; Thompson DA; Petersen-Jones SM; Michaelides M; van den Born LI; Stockman A; Smith AJ; Rubin G; Ali RR
N Engl J Med; 2015 May; 372(20):1887-97. PubMed ID: 25938638
[TBL] [Abstract][Full Text] [Related]
5. Safety and Long-Term Efficacy of AAV4 Gene Therapy in Patients with RPE65 Leber Congenital Amaurosis.
Le Meur G; Lebranchu P; Billaud F; Adjali O; Schmitt S; Bézieau S; Péréon Y; Valabregue R; Ivan C; Darmon C; Moullier P; Rolling F; Weber M
Mol Ther; 2018 Jan; 26(1):256-268. PubMed ID: 29033008
[TBL] [Abstract][Full Text] [Related]
6. Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium.
Le Meur G; Stieger K; Smith AJ; Weber M; Deschamps JY; Nivard D; Mendes-Madeira A; Provost N; Péréon Y; Cherel Y; Ali RR; Hamel C; Moullier P; Rolling F
Gene Ther; 2007 Feb; 14(4):292-303. PubMed ID: 17024105
[TBL] [Abstract][Full Text] [Related]
7. Results at 5 Years After Gene Therapy for RPE65-Deficient Retinal Dystrophy.
Pennesi ME; Weleber RG; Yang P; Whitebirch C; Thean B; Flotte TR; Humphries M; Chegarnov E; Beasley KN; Stout JT; Chulay JD
Hum Gene Ther; 2018 Dec; 29(12):1428-1437. PubMed ID: 29869534
[TBL] [Abstract][Full Text] [Related]
8. Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy.
Weleber RG; Pennesi ME; Wilson DJ; Kaushal S; Erker LR; Jensen L; McBride MT; Flotte TR; Humphries M; Calcedo R; Hauswirth WW; Chulay JD; Stout JT
Ophthalmology; 2016 Jul; 123(7):1606-20. PubMed ID: 27102010
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years.
Jacobson SG; Cideciyan AV; Ratnakaram R; Heon E; Schwartz SB; Roman AJ; Peden MC; Aleman TS; Boye SL; Sumaroka A; Conlon TJ; Calcedo R; Pang JJ; Erger KE; Olivares MB; Mullins CL; Swider M; Kaushal S; Feuer WJ; Iannaccone A; Fishman GA; Stone EM; Byrne BJ; Hauswirth WW
Arch Ophthalmol; 2012 Jan; 130(1):9-24. PubMed ID: 21911650
[TBL] [Abstract][Full Text] [Related]
10. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial.
Hauswirth WW; Aleman TS; Kaushal S; Cideciyan AV; Schwartz SB; Wang L; Conlon TJ; Boye SL; Flotte TR; Byrne BJ; Jacobson SG
Hum Gene Ther; 2008 Oct; 19(10):979-90. PubMed ID: 18774912
[TBL] [Abstract][Full Text] [Related]
11. Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65.
Georgiadis A; Duran Y; Ribeiro J; Abelleira-Hervas L; Robbie SJ; Sünkel-Laing B; Fourali S; Gonzalez-Cordero A; Cristante E; Michaelides M; Bainbridge JW; Smith AJ; Ali RR
Gene Ther; 2016 Dec; 23(12):857-862. PubMed ID: 27653967
[TBL] [Abstract][Full Text] [Related]
12. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement.
Cideciyan AV; Jacobson SG; Beltran WA; Sumaroka A; Swider M; Iwabe S; Roman AJ; Olivares MB; Schwartz SB; Komáromy AM; Hauswirth WW; Aguirre GD
Proc Natl Acad Sci U S A; 2013 Feb; 110(6):E517-25. PubMed ID: 23341635
[TBL] [Abstract][Full Text] [Related]
13. Clinical gene therapy for the treatment of RPE65-associated Leber congenital amaurosis.
Stein L; Roy K; Lei L; Kaushal S
Expert Opin Biol Ther; 2011 Mar; 11(3):429-39. PubMed ID: 21299439
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy rescues cone structure and function in the 3-month-old rd12 mouse: a model for midcourse RPE65 leber congenital amaurosis.
Li X; Li W; Dai X; Kong F; Zheng Q; Zhou X; Lü F; Chang B; Rohrer B; Hauswirth WW; Qu J; Pang JJ
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):7-15. PubMed ID: 21169527
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Structural Outcomes of Late-Stage RPE65 Gene Therapy.
Gardiner KL; Cideciyan AV; Swider M; Dufour VL; Sumaroka A; Komáromy AM; Hauswirth WW; Iwabe S; Jacobson SG; Beltran WA; Aguirre GD
Mol Ther; 2020 Jan; 28(1):266-278. PubMed ID: 31604676
[TBL] [Abstract][Full Text] [Related]
16. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness.
Acland GM; Aguirre GD; Bennett J; Aleman TS; Cideciyan AV; Bennicelli J; Dejneka NS; Pearce-Kelling SE; Maguire AM; Palczewski K; Hauswirth WW; Jacobson SG
Mol Ther; 2005 Dec; 12(6):1072-82. PubMed ID: 16226919
[TBL] [Abstract][Full Text] [Related]
17. Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis.
Jacobson SG; Boye SL; Aleman TS; Conlon TJ; Zeiss CJ; Roman AJ; Cideciyan AV; Schwartz SB; Komaromy AM; Doobrajh M; Cheung AY; Sumaroka A; Pearce-Kelling SE; Aguirre GD; Kaushal S; Maguire AM; Flotte TR; Hauswirth WW
Hum Gene Ther; 2006 Aug; 17(8):845-58. PubMed ID: 16942444
[TBL] [Abstract][Full Text] [Related]
18. Lentiviral gene transfer of RPE65 rescues survival and function of cones in a mouse model of Leber congenital amaurosis.
Bemelmans AP; Kostic C; Crippa SV; Hauswirth WW; Lem J; Munier FL; Seeliger MW; Wenzel A; Arsenijevic Y
PLoS Med; 2006 Oct; 3(10):e347. PubMed ID: 17032058
[TBL] [Abstract][Full Text] [Related]
19. Functional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog.
Narfström K; Katz ML; Bragadottir R; Seeliger M; Boulanger A; Redmond TM; Caro L; Lai CM; Rakoczy PE
Invest Ophthalmol Vis Sci; 2003 Apr; 44(4):1663-72. PubMed ID: 12657607
[TBL] [Abstract][Full Text] [Related]
20. The Status of RPE65 Gene Therapy Trials: Safety and Efficacy.
Pierce EA; Bennett J
Cold Spring Harb Perspect Med; 2015 Jan; 5(9):a017285. PubMed ID: 25635059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
